vk2735 viking therapeutics news - Search News

Viking Therapeutics, VK2735

Seeking Alpha · 1d

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term prospects remain positive.

Business Insider · 1d

Promising Phase 1 Results for Viking Therapeutics’ VK2735: Analyst Recommends Buy Rating

Michael Ulz, an analyst from Morgan Stanley, reiterated the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated

Il Messaggero · 19h

Viking Therapeutics' New Weight Loss Pill Shows Promising Results

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories of the American company Viking Therapeutics, which has achieved a

1don MSN

Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results

Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...

2d

Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety

Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...

The Motley Fool on MSN1d

Is Viking Therepautics a Buy Now?

Wall Street's been pounding the table on Viking Therapeutics because VK2735 could become the next and best dual ...

18h

Viking Therapeutics Offers An Obesity Drug for Healthy Adults

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

1don MSN

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...

GlobalData on MSN21h

Viking stock fluctuates amid manufacturing concerns with obesity pill

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

1d

Wall Street Lunch: Viking Weight-Loss Pill Data Is Striking

Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results